Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Reactogenicity of BNT162b2 COVID-19 Vaccine in Thai Adolescents with Chronic Diseases
TCTR20210826001Completed
- Sponsor
- Pediatric Infectious Disease Society of Thailand
- Start
- Aug 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Pediatric Infectious Disease Society of Thailand. Primary endpoints: Immunogenicity and Reactogenicity. Started Aug 2021; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20210826001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210826001.